Group 1 - Sichuan Baili Tianheng Pharmaceutical Co., Ltd., WeDoctor Holdings Limited, Betta Pharmaceuticals Co., Ltd., Dajin Heavy Industry Co., Ltd., and LEO Group Co., Ltd. submitted listing applications to the Hong Kong Stock Exchange on September 29, aiming for a main board listing [1]. Group 2 - The companies are seeking to raise capital through the issuance of H-shares, with each H-share having a par value of RMB 1.00 [4][10][16]. - The underwriting process involves several joint sponsors, including Goldman Sachs, J.P. Morgan, Morgan Stanley, and CITIC Securities, among others [4][10][12].

Group 1 - The Hang Seng Technology ETF Tianhong (520920) is set to be listed on September 30, 2025, with a total of 6,018 account holders and an average holding of 202,728.32 shares per account as of September 23, 2025 [1] - The ETF closely tracks the Hang Seng Technology Index, which consists of the top 30 Hong Kong stocks related to technology, covering sectors such as information technology, consumer discretionary, and communication services [1] - The Hang Seng Technology Index shows superior earnings growth, with a revenue year-on-year growth rate of 14.43% and a net profit growth rate of 16.18% in Q2 2025, outperforming other major Hong Kong indices [1] Group 2 - There is a continuing trend of A-share companies planning to list in Hong Kong, with 18 companies disclosing plans to do so as of September 28, including notable names like Five Fragrance Zhai and East Mountain Precision [2] - Short-term market fluctuations are expected due to seasonal effects, but the overall bull market is anticipated to continue, supported by ample micro liquidity and policies aimed at stabilizing the stock market [2] - Chinese companies are demonstrating global competitiveness in sectors such as artificial intelligence, biomedicine, and high-end manufacturing, maintaining a high level of activity in the technology sector [2] Group 3 - The initiation of a Federal Reserve rate cut cycle is expected to support a continued upward trend in the Hong Kong stock market, which has strong overall profitability and relatively low valuations [3] - The scarcity of assets in sectors like internet, new consumption, and innovative pharmaceuticals contributes to the attractiveness of long-term investments in the Hong Kong market [3] - The ongoing development of the AI industry is likely to drive further value reassessment of Hong Kong-listed Chinese technology companies [3]

Group 1 - The core viewpoint of the article highlights the ongoing trend of A-share companies planning to list in Hong Kong, with 18 companies disclosing their intentions to do so in September 2023 [1] - Among these companies, Dongshan Precision announced on September 23 its plan to issue H-shares and list on the Hong Kong Stock Exchange [1] - The list of companies includes notable names such as Wufangzhai, Borui Pharmaceutical, and Haierland, indicating a broad interest across various sectors [1]

证券代码：300558 证券简称：贝达药业 公告编号：2025-066 贝达药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会没有涉及变更前次股东大会决议。 一、会议召开和出席情况 贝达药业股份有限公司（以下简称"公司"）2025 年第一次临时股东大会会 议通知于 2025 年 9 月 10 日以公告形式发出，现场会议于 2025 年 9 月 26 日（星 期五）14:30 在公司行政大楼一楼会议室召开，通过深圳证券交易所交易系统进 行网络投票的具体时间为 2025 年 9 月 26 日的交易时间，即 9:15-9:25、9:30-11:30、 13:00-15:00；通过深圳证券交易所互联网投票系统进行投票的具体时间为 2025 年 9 月 26 日 9:15-15:00 期间的任意时间。 本次股东大会采取现场投票和网络投票相结合的方式召开。通过现场和网络 投票的股东及股东授权委托代表 286 人，代表股份 199,299,693 股 ...

国浩律师（杭州）事务所 贝达药业 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 关于 贝达药业股份有限公司 2025 年第一次临时股东大会 的 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年九月 国浩律师（杭州）事务所 贝达药业 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 关于 贝达药业股份有限公司 2025 年第一次临时股东大会的法律意见书 致：贝达药业股份有限公司 国浩律师（杭州）事务所（以下简称本所）接受贝达药业股份有限公司（以 下简 ...

Core Viewpoint - The article discusses the challenges faced by Betta Pharmaceuticals, particularly the decline in profitability and the impact of product competition on its financial health, leading to a liquidity crisis and the need for a third attempt at an IPO in Hong Kong [6][14]. Financial Performance - In the first half of 2025, Betta Pharmaceuticals reported a revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but the net profit dropped by 37.53% to 140 million yuan, indicating a dangerous trend of "increased revenue without increased profit" [7][10]. - The second quarter of 2025 saw a significant decline in profitability, with a revenue of 814 million yuan corresponding to a net profit of 39.808 million yuan, a staggering year-on-year decrease of 68.36% [7][10]. Product Challenges - The core product, Camrelizumab (凯美纳), has seen a cumulative price drop of 54% due to multiple rounds of medical insurance negotiations and is facing competition from generics after its patent expiration in 2023, leading to stagnation in growth [6][8]. - Another key product, Ensartinib (贝美纳), is under pressure with a 71% price reduction and competition from five similar products in the European market, resulting in declining gross margins [8][9]. - The third-generation EGFR inhibitor, Bafetinib (贝福替尼), has not met sales expectations, with first-half sales failing to reach the disclosure threshold of 173 million yuan, significantly below the market expectation of 1 billion yuan [8][9]. Research and Development (R&D) Issues - Betta Pharmaceuticals has reduced its R&D investment from 700 million yuan in 2022 to 500 million yuan in 2024, with only 226 million yuan spent in the first half of 2025, a year-on-year decrease of 10.4% [9][15]. - The R&D team size has halved from 647 to 327, contrasting sharply with the industry trend where A-share innovative pharmaceutical companies increased R&D investment by 18% in the same period [9][15]. Cash Flow and Debt Situation - The company's operating cash flow has deteriorated, with a net cash flow from operating activities of 445 million yuan in the first half of 2025, a decline of 14.7% year-on-year [10][11]. - As of June 2025, current liabilities exceeded current assets by 398 million yuan, resulting in a current ratio of only 0.77, indicating significant short-term debt repayment pressure [10][11]. IPO Attempts and Market Conditions - Betta Pharmaceuticals announced its third attempt at an IPO in September 2025, aiming to issue up to 15% of its total shares, with the primary goal of alleviating liquidity issues [14][16]. - The previous two IPO attempts in 2021 were unsuccessful due to deteriorating financial conditions and market sentiment, with the second application expiring in June 2022 [13][14]. Industry Context - The challenges faced by Betta Pharmaceuticals reflect broader issues within the Chinese innovative pharmaceutical sector, including price controls, intensified competition, and a decline in new drug applications [14][15]. - The article highlights the need for companies to adapt by focusing on new global targets and improving cost control to survive in a competitive landscape [15][16].

Investment Rating - The report assigns a mid-to-low level investment rating to He Yuan Bio, with an AHP score of 2.59, placing it in the 42.6% percentile of the AHP model [7]. Core Insights - He Yuan Bio is a pioneer in the "rice blood production" industry, having launched the first recombinant human albumin product in China, which was approved in July 2025. This product addresses the market for liver cirrhosis with low albumin levels, which constitutes about 30% of the human serum albumin market [9][14]. - The company has developed two major technology platforms: the OryzHiExp for efficient recombinant protein expression and the OryzPur for protein purification, achieving high purity levels and cost reductions [17]. - He Yuan Bio has a robust pipeline with eight products in development or on the market, targeting various clinical needs across different age groups, thus reducing dependency on any single area [9][14]. Summary by Sections AHP Score and Expected Allocation Ratio - He Yuan Bio's AHP score is calculated to be 2.59, indicating a mid-to-low ranking within the AHP model [7]. - The offline issuance adopts a lock-up mechanism with varying lock-up ratios and periods for different classes of investors [7]. Company Highlights and Features - He Yuan Bio is recognized as the first company to utilize rice endosperm cell bioreactors for large-scale production of pharmaceutical proteins, with a focus on recombinant human albumin [9]. - The company has established a comprehensive sales network across over 30 provinces in China and is preparing for negotiations to enter the national medical insurance directory [21]. - The company has cultivated over 9,000 acres of medicinal rice to ensure a stable supply of raw materials for production [18]. Financial Comparison with Peers - He Yuan Bio has only one product on the market compared to an average of four for comparable companies, indicating a relatively slower development pipeline [25]. - The company's revenue and net profit figures are lower than those of comparable companies, primarily due to the lack of market-ready products [27]. - R&D expenses have shown a compound annual growth rate of 2.8%, slightly above the average of comparable firms [33]. Fundraising Projects and Development Vision - The company plans to use the funds raised from its IPO for the construction of a recombinant human albumin industrialization base, new drug development projects, and to supplement working capital [43]. - The industrialization base project aims to enhance production capacity and meet the growing market demand for human serum albumin [19].

Core Viewpoint - Bidda Pharmaceutical is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and competitiveness, while also advancing its internationalization process [1] Group 1: Financial Performance - For the first half of 2025, Bidda Pharmaceutical reported revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but the net profit attributable to shareholders dropped by 37.53% to 140 million yuan, marking the first half-year profit decline since 2022 [2] - The company's second-quarter performance showed a revenue of 814 million yuan, a slight increase of 6.39%, while net profit fell significantly by 68.36% to 39.81 million yuan [2] Group 2: Debt and Financial Pressure - Bidda Pharmaceutical is facing financial pressure, with current assets of 1.359 billion yuan against current liabilities of 1.757 billion yuan as of mid-2023, resulting in a cash and cash equivalents balance of 527 million yuan [4] - The company has an outstanding payment of 180 million yuan to Yifang Bio for a milestone payment related to a lung cancer drug project, which has been overdue for nearly two years [3] - As of the first half of 2025, the total accounts payable amounted to 580 million yuan, with 180 million yuan being overdue payments to Yifang Bio [3] Group 3: Research and Development - Bidda Pharmaceutical's R&D investment has been declining, dropping from 700 million yuan in 2022 to 500 million yuan in 2024, with only 255 million yuan spent in the first half of 2025, a slight decrease of 0.63% year-on-year [3]

Core Viewpoint - Betta Pharmaceuticals is making a third attempt to list on the Hong Kong Stock Exchange (HKEX) after two previous unsuccessful attempts in 2021, raising questions about its ability to pass HKEX scrutiny and achieve its listing goals [1][2]. Group 1: Company Overview - Betta Pharmaceuticals focuses on innovative drug research and development, integrating R&D, production, and marketing [2]. - The company has eight marketed products targeting various cancers, including lung, kidney, and breast cancer [2]. - Betta Pharmaceuticals was listed on the Shenzhen Stock Exchange in 2016 [2]. Group 2: Financial Performance - In the first half of 2025, Betta Pharmaceuticals reported a revenue of 1.731 billion yuan, a year-on-year increase of 15.37%, but net profit fell by 37.53% to 140 million yuan [2][3]. - The second quarter of 2025 saw a significant net profit decline of 68.36%, marking the first instance of a year-on-year decrease in net profit since 2023 [2]. Group 3: Cost Structure - The decline in net profit is attributed to increased depreciation and amortization expenses [3]. - R&D expenses decreased by 10.40% to 226 million yuan, while sales expenses rose by 13.34% to 594 million yuan [3]. Group 4: Financial Pressure - As of June 30, 2025, Betta Pharmaceuticals had current assets of 1.359 billion yuan, which is lower than current liabilities of 1.757 billion yuan, indicating short-term solvency issues [4]. - The net cash flow from operating activities was 445 million yuan, a decrease of 14.70% year-on-year, highlighting liquidity challenges [4]. Group 5: Debt Issues - Betta Pharmaceuticals has an outstanding payment of 180 million yuan to Yifang Bio for a collaboration agreement, with some payments overdue for over two years [4][5]. - The company has marked the reason for the unpaid amount as "not yet settled," indicating ongoing disputes [5]. Group 6: Product Dependency - The company's net profit margin dropped to 7.55%, down from 14.40% in the previous year, largely due to high dependency on core products and a lack of new product support [6]. - The main revenue drivers are two products, Kai Mei Na and Bei Mei Na, which have historically contributed significantly to revenue [6]. Group 7: Market Competition - The third-generation EGFR inhibitor, Sai Mei Na, has not performed as expected in the market, with sales failing to meet the threshold of 10% of total revenue [7]. - New products like Kang Mei Na and Ao Fu Min face stiff competition from established players, limiting their potential revenue contributions [8]. Group 8: Future Outlook - The company aims to use the funds raised from the IPO for R&D, potential acquisitions, and expanding its marketing network [5]. - The ability of Betta Pharmaceuticals to navigate current challenges and achieve its IPO goals remains a focal point for market observers [8].

化学制药板块震荡拉升，信立泰、向日葵双双涨停，康芝药业、海创药业-U、海辰药业、贝达药业、 盟科药业-U、键凯科技等跟涨。 ...